281 related articles for article (PubMed ID: 25042049)
1. Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model.
Flemming JA; Yang JD; Vittinghoff E; Kim WR; Terrault NA
Cancer; 2014 Nov; 120(22):3485-93. PubMed ID: 25042049
[TBL] [Abstract][Full Text] [Related]
2. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.
Ioannou GN; Green P; Kerr KF; Berry K
J Hepatol; 2019 Sep; 71(3):523-533. PubMed ID: 31145929
[TBL] [Abstract][Full Text] [Related]
3. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease.
Lok AS; Seeff LB; Morgan TR; di Bisceglie AM; Sterling RK; Curto TM; Everson GT; Lindsay KL; Lee WM; Bonkovsky HL; Dienstag JL; Ghany MG; Morishima C; Goodman ZD;
Gastroenterology; 2009 Jan; 136(1):138-48. PubMed ID: 18848939
[TBL] [Abstract][Full Text] [Related]
4. [Not Available].
Medhioub M; Khsiba A; Mahmoudi M; Ben Mohamed A; Yakoubi M; Hamzaoui L
Tunis Med; 2023 Apr; 101(4):420-425. PubMed ID: 38372534
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective cohort analysis.
Sasaki K; Firl DJ; Hashimoto K; Fujiki M; Diago-Uso T; Quintini C; Eghtesad B; Fung JJ; Aucejo FN; Miller CM
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):595-603. PubMed ID: 28546007
[TBL] [Abstract][Full Text] [Related]
6. Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir.
Yu JH; Suh YJ; Jin YJ; Heo NY; Jang JW; You CR; An HY; Lee JW
Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):865-872. PubMed ID: 30694912
[TBL] [Abstract][Full Text] [Related]
7. Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C.
Ioannou GN; Green PK; Beste LA; Mun EJ; Kerr KF; Berry K
J Hepatol; 2018 Nov; 69(5):1088-1098. PubMed ID: 30138686
[TBL] [Abstract][Full Text] [Related]
8. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.
van der Meer AJ; Feld JJ; Hofer H; Almasio PL; Calvaruso V; Fernández-Rodríguez CM; Aleman S; Ganne-Carrié N; D'Ambrosio R; Pol S; Trapero-Marugan M; Maan R; Moreno-Otero R; Mallet V; Hultcrantz R; Weiland O; Rutter K; Di Marco V; Alonso S; Bruno S; Colombo M; de Knegt RJ; Veldt BJ; Hansen BE; Janssen HLA
J Hepatol; 2017 Mar; 66(3):485-493. PubMed ID: 27780714
[TBL] [Abstract][Full Text] [Related]
9. Risk of hepatocellular carcinoma among individuals with different aetiologies of cirrhosis: a population-based cohort study.
West J; Card TR; Aithal GP; Fleming KM
Aliment Pharmacol Ther; 2017 Apr; 45(7):983-990. PubMed ID: 28144999
[TBL] [Abstract][Full Text] [Related]
10. Development of Risk Prediction Model for Hepatocellular Carcinoma Progression of Indeterminate Nodules in Hepatitis B Virus-Related Cirrhotic Liver.
Cho HJ; Kim B; Lee JD; Kang DR; Kim JK; Lee JH; Shin SJ; Lee KM; Yoo BM; Lee KJ; Kim SS; Cheong JY; Cho SW
Am J Gastroenterol; 2017 Mar; 112(3):460-470. PubMed ID: 27779194
[TBL] [Abstract][Full Text] [Related]
11. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.
Nahon P; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Roudot-Thoraval F; Audureau E;
Gastroenterology; 2018 Nov; 155(5):1436-1450.e6. PubMed ID: 30031138
[TBL] [Abstract][Full Text] [Related]
12. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
13. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
[TBL] [Abstract][Full Text] [Related]
14. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.
Papatheodoridis G; Dalekos G; Sypsa V; Yurdaydin C; Buti M; Goulis J; Calleja JL; Chi H; Manolakopoulos S; Mangia G; Gatselis N; Keskin O; Savvidou S; de la Revilla J; Hansen BE; Vlachogiannakos I; Galanis K; Idilman R; Colombo M; Esteban R; Janssen HL; Lampertico P
J Hepatol; 2016 Apr; 64(4):800-6. PubMed ID: 26678008
[TBL] [Abstract][Full Text] [Related]
15. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles.
Lee MH; Yang HI; Liu J; Batrla-Utermann R; Jen CL; Iloeje UH; Lu SN; You SL; Wang LY; Chen CJ;
Hepatology; 2013 Aug; 58(2):546-54. PubMed ID: 23504622
[TBL] [Abstract][Full Text] [Related]
16. Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis.
Colapietro F; Maisonneuve P; Lytvyak E; Beuers U; Verdonk RC; van der Meer AJ; van Hoek B; Kuiken SD; Brouwer JT; Muratori P; Aghemo A; Carella F; van den Berg AP; Zachou K; Dalekos GN; Di Zeo-Sánchez DE; Robles M; Andrade RJ; Montano-Loza AJ; van den Brand FF; Slooter CD; Macedo G; Liberal R; de Boer YS; Lleo A; ;
J Hepatol; 2024 Jan; 80(1):53-61. PubMed ID: 37802188
[TBL] [Abstract][Full Text] [Related]
17. Validation of the Toronto hepatocellular carcinoma risk index for patients with cirrhosis in China: a retrospective cohort study.
Zhang H; Zhu J; Xi L; Xu C; Wu A
World J Surg Oncol; 2019 Apr; 17(1):75. PubMed ID: 31039803
[TBL] [Abstract][Full Text] [Related]
18. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B.
Hsu YC; Yip TC; Ho HJ; Wong VW; Huang YT; El-Serag HB; Lee TY; Wu MS; Lin JT; Wong GL; Wu CY
J Hepatol; 2018 Aug; 69(2):278-285. PubMed ID: 29551708
[TBL] [Abstract][Full Text] [Related]
19. Deep learning model for prediction of hepatocellular carcinoma in patients with HBV-related cirrhosis on antiviral therapy.
Nam JY; Sinn DH; Bae J; Jang ES; Kim JW; Jeong SH
JHEP Rep; 2020 Dec; 2(6):100175. PubMed ID: 33117971
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for hepatocellular carcinoma in patients with liver cirrhosis.
Macías Rodríguez MA; Rendón Unceta P; Tejada Cabrera M; Infante Hernández JM; Correro Aguilar F; Díaz García F; Benítez Rodríguez E; Mangas Rojas A; Martín Herrera L
Rev Esp Enferm Dig; 2000 Jul; 92(7):458-69. PubMed ID: 11026763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
